Assessment of pulmonary function in COPD

被引:23
作者
Cooper, CB
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA
关键词
pulmonary function testing; COPD; screening spirometry; body plethysmography; impulse oscillometry; preoperative assessment;
D O I
10.1055/s-2005-869543
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Pulmonary function testing is used in the diagnosis of chronic obstructive pulmonary disease (COPD) and the staging of COPD severity. The current diagnostic criterion for airflow obstruction is a ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) < 70%. However this absolute definition can lead to false-negative determinations in younger patients and false-positive determinations in the elderly. Nevertheless, screening spirometry is advocated and becomes feasible in the physician office setting with the availability of compact, relatively affordable apparatus that meets the appropriate technical specifications. Spirometry should be complemented by measurement of lung volumes using body plethysmography in those with evidence of airflow obstruction. Small airways disease can be detected by various techniques that measure airway and total respiratory system resistance. There is renewed interest in the forced oscillation technique and impulse oscillometry because of their noninvasiveness and potential ability to distinguish small from larger air-way disease. Finally, pulmonary function testing has an important role in preoperative risk assessment; for example, in patients being considered for lung volume reduction surgery or resection of a lung nodule.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 46 条
[1]
[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185
[2]
[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107
[3]
VARIABILITY OF BREATHLESSNESS MEASUREMENT IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
BELMAN, MJ ;
BROOKS, LR ;
ROSS, DJ ;
MOHSENIFAR, Z .
CHEST, 1991, 99 (03) :566-571
[4]
BONE R, 1994, CHEST, V105, P1411
[5]
A COMPARISON OF THE EFFECT OF IPRATROPIUM AND ALBUTEROL IN THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASE [J].
BRAUN, SR ;
MCKENZIE, WN ;
COPELAND, C ;
KNIGHT, L ;
ELLERSIECK, M .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (03) :544-547
[6]
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].
Brusasco, V ;
Hodder, R ;
Miravitlles, M ;
Korducki, L ;
Towse, L ;
Kesten, S .
THORAX, 2003, 58 (05) :399-404
[7]
Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes [J].
Celli, B ;
ZuWallack, R ;
Wang, S ;
Kesten, S .
CHEST, 2003, 124 (05) :1743-1748
[8]
DOSE-RESPONSE RELATION TO ORAL THEOPHYLLINE IN SEVERE CHRONIC OBSTRUCTIVE AIRWAYS DISEASE [J].
CHRYSTYN, H ;
MULLEY, BA ;
PEAKE, MD .
BRITISH MEDICAL JOURNAL, 1988, 297 (6662) :1506-1510
[9]
Measurement of lung volumes in humans: Review and recommendations from an ATS/ERS workshop [J].
Clausen, JL ;
Coates, AL ;
Quanjer, PH .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (06) :1205-1206
[10]
Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease [J].
Cooper, CB ;
Tashkin, DP .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7492) :640-644